(Created page with "<html > <head> <meta charset="UTF-8"> <title>Barriers to Entry</title> <link href="https://fonts.googleapis.com/css?family=Fjalla+One" rel="stylesheet"> <lin...") |
|||
Line 59: | Line 59: | ||
font-size: 20px; | font-size: 20px; | ||
+ | } | ||
+ | html, | ||
+ | body { | ||
+ | margin: 0; | ||
+ | } | ||
+ | |||
+ | #preloader { | ||
+ | position: absolute; | ||
+ | width: 100%; | ||
+ | height: 100%; | ||
+ | background: white; | ||
+ | } | ||
+ | |||
+ | #discoveryChart { | ||
+ | position: absolute; | ||
+ | width: 620px; | ||
+ | height: 240px; | ||
+ | margin: auto; | ||
+ | top: 0; | ||
+ | left: 0; | ||
+ | right: 0; | ||
+ | bottom: 0; | ||
+ | } | ||
+ | |||
+ | #pieContainer { | ||
+ | position: absolute; | ||
+ | width: 240px; | ||
+ | height: 240px; | ||
+ | left: 0; | ||
+ | overflow: visible; | ||
+ | } | ||
+ | |||
+ | #discoveryTextContainer { | ||
+ | position: absolute; | ||
+ | width: 380px; | ||
+ | height: 240px; | ||
+ | left: 260px; | ||
+ | } | ||
+ | |||
+ | #lines { | ||
+ | position: absolute; | ||
+ | margin: auto; | ||
+ | top: 0; | ||
+ | left: 0; | ||
+ | right: 0; | ||
+ | bottom: 0; | ||
+ | } | ||
+ | |||
+ | #line1, | ||
+ | #line2, | ||
+ | #line3, | ||
+ | #line4 { | ||
+ | fill:none; | ||
+ | stroke-width:1; | ||
+ | stroke-miterlimit:10; | ||
+ | stroke-dasharray: 50; | ||
+ | stroke-dashoffset: -50; | ||
+ | } | ||
+ | |||
+ | #line1{ | ||
+ | stroke:#BCCF00; | ||
+ | } | ||
+ | #line2{ | ||
+ | stroke:#F6A000; | ||
+ | } | ||
+ | #line3{ | ||
+ | stroke:#009FE3; | ||
+ | } | ||
+ | #line4{ | ||
+ | stroke:#E84E0F; | ||
+ | } | ||
+ | |||
+ | #chart { | ||
+ | position: absolute; | ||
+ | overflow: visible; | ||
+ | } | ||
+ | |||
+ | #green { | ||
+ | fill:#BCCF00; | ||
+ | } | ||
+ | |||
+ | #orange { | ||
+ | fill:#F6A000; | ||
+ | } | ||
+ | |||
+ | #blue { | ||
+ | fill:#009FE3; | ||
+ | } | ||
+ | |||
+ | #red { | ||
+ | fill:#E84E0F; | ||
+ | } | ||
+ | |||
+ | #leftBar { | ||
+ | display: inline-block; | ||
+ | background-color: #E84E0F; | ||
+ | width: 6px; | ||
+ | height: 100%; | ||
+ | } | ||
+ | |||
+ | .title { | ||
+ | width: 100%; | ||
+ | } | ||
+ | |||
+ | #discoveryTextContainer { | ||
+ | border-left: 0px solid #EEE; | ||
+ | } | ||
+ | |||
+ | .title h2 { | ||
+ | position: absolute; | ||
+ | font-family: 'Fjalla One'; | ||
+ | text-transform: uppercase; | ||
+ | font-size: 28px; | ||
+ | margin-top: 14px; | ||
+ | left: 20px; | ||
+ | visibility: hidden; | ||
+ | } | ||
+ | |||
+ | .title p { | ||
+ | position: absolute; | ||
+ | font-family: Georgia, Serif; | ||
+ | margin-left: 20px; | ||
+ | top: 48px; | ||
+ | visibility: hidden; | ||
} | } | ||
</style> | </style> | ||
Line 121: | Line 245: | ||
<script src='https://cdnjs.cloudflare.com/ajax/libs/gsap/1.19.0/TweenMax.min.js'></script> | <script src='https://cdnjs.cloudflare.com/ajax/libs/gsap/1.19.0/TweenMax.min.js'></script> | ||
− | <script | + | <script> |
+ | var firstMove = true; | ||
+ | var active; | ||
+ | var tl; | ||
+ | |||
+ | var g = document.getElementById('green'); | ||
+ | var o = document.getElementById('orange'); | ||
+ | var b = document.getElementById('blue'); | ||
+ | var r = document.getElementById('red'); | ||
+ | |||
+ | var dc = document.getElementById('discoveryChart'); | ||
+ | |||
+ | function setup() { | ||
+ | TweenMax.set('#chart', {scale: 0}); | ||
+ | TweenMax.set('#lines', {scale: 1.5 }); | ||
+ | TweenMax.set(['#description h2', '#titleOne h2','#titleTwo h2','#titleThree h2','#titleFour h2'], { x: '-=8' }); | ||
+ | TweenMax.to('#preloader', 0.25, { autoAlpha: 0 }); | ||
+ | animate(); | ||
+ | listeners(); | ||
+ | }; | ||
+ | |||
+ | function animate() { | ||
+ | TweenMax.to(['#line1','#line2','#line3','#line4'], 1.25, { strokeDashoffset: 50, ease: Power3.easeInOut }); | ||
+ | TweenMax.to('#chart', 1.5, { scale: 1, ease: Power3.easeOut, delay: .84 }); | ||
+ | TweenMax.to(['#description h2', '#description p'], 1.5, { x: 0, autoAlpha: 1, ease: Power3.easeOut }); | ||
+ | |||
+ | tl = new TimelineMax(); | ||
+ | }; | ||
+ | |||
+ | function listeners() { | ||
+ | |||
+ | g.addEventListener('click', highlightGreen); | ||
+ | |||
+ | o.addEventListener('click', highlightOrange); | ||
+ | |||
+ | b.addEventListener('click', highlightBlue); | ||
+ | |||
+ | r.addEventListener('click', highlightRed); | ||
+ | |||
+ | }; | ||
+ | |||
+ | function removeDescription() { | ||
+ | TweenMax.to(['#description h2', '#description p'], 1, { autoAlpha: 0, ease: Linear.easeNone }); | ||
+ | }; | ||
+ | |||
+ | function highlightGreen() { | ||
+ | |||
+ | removeDescription(); | ||
+ | |||
+ | if (active === 'orange') { | ||
+ | placeOrange(); | ||
+ | } else if (active === 'blue') { | ||
+ | placeBlue(); | ||
+ | } else if (active === 'red') { | ||
+ | placeRed(); | ||
+ | } | ||
+ | |||
+ | active = 'green'; | ||
+ | |||
+ | tl.to('#green', .5, { x: -10, y: -10, ease: Power3.easeOut }); | ||
+ | tl.to('#discoveryTextContainer', .5, { borderLeft: '6px solid #BCCF00', ease: Linear.easeNone }); | ||
+ | tl.to('#titleOne h2', .5, { x: 0, autoAlpha: 1, ease: Linear.easeNone }, '-=0.25'); | ||
+ | tl.to('#titleOne p', .5, { autoAlpha: 1, ease: Linear.easeNone }, '-=.5'); | ||
+ | |||
+ | }; | ||
+ | function placeGreen() { | ||
+ | tl.to('#green', .5, { x: 0, y: 0, ease: Power3.easeOut }); | ||
+ | tl.to('#discoveryTextContainer', .5, { borderLeft: '0px solid #EEE', ease: Linear.easeNone }); | ||
+ | tl.to('#titleOne h2', .5, { x: '-=8', autoAlpha: 0, ease: Linear.easeNone }, '-=0.5'); | ||
+ | tl.to('#titleOne p', .5, { autoAlpha: 0, ease: Linear.easeNone }, '-=.5'); | ||
+ | }; | ||
+ | |||
+ | function highlightOrange() { | ||
+ | |||
+ | removeDescription(); | ||
+ | |||
+ | if (active === 'blue') { | ||
+ | placeBlue(); | ||
+ | } else if (active === 'green') { | ||
+ | placeGreen(); | ||
+ | } else if (active === 'red') { | ||
+ | placeRed(); | ||
+ | } | ||
+ | |||
+ | active = 'orange'; | ||
+ | |||
+ | tl.to('#orange', .5, { x: 8, y: -10, ease: Power3.easeOut }); | ||
+ | tl.to('#discoveryTextContainer', .5, { borderLeft: '6px solid #F6A000', ease: Linear.easeNone }); | ||
+ | tl.to('#titleTwo h2', .5, { x: '0', autoAlpha: 1, ease: Linear.easeNone }, '-=0.25'); | ||
+ | tl.to('#titleTwo p', .5, { autoAlpha: 1, ease: Linear.easeNone }, '-=.5'); | ||
+ | }; | ||
+ | function placeOrange() { | ||
+ | tl.to('#orange', .5, { x: 0, y: 0, ease: Power3.easeOut }); | ||
+ | tl.to('#discoveryTextContainer', .5, { borderLeft: '0px solid #EEE', ease: Linear.easeNone }); | ||
+ | tl.to('#titleTwo h2', .5, { x: '-=8', autoAlpha: 0, ease: Linear.easeNone }, '-=0.5'); | ||
+ | tl.to('#titleTwo p', .5, { autoAlpha: 0, ease: Linear.easeNone }, '-=.5'); | ||
+ | }; | ||
+ | |||
+ | function highlightBlue() { | ||
+ | |||
+ | removeDescription(); | ||
+ | |||
+ | if (active === 'green') { | ||
+ | placeGreen(); | ||
+ | } else if (active === 'orange') { | ||
+ | placeOrange(); | ||
+ | } else if (active === 'red') { | ||
+ | placeRed(); | ||
+ | } | ||
+ | |||
+ | active = 'blue'; | ||
+ | |||
+ | tl.to('#blue', .5, { x: -2, y: 12, ease: Power3.easeOut }); | ||
+ | tl.to('#discoveryTextContainer', .5, { borderLeft: '6px solid #009FE3', ease: Linear.easeNone }); | ||
+ | tl.to('#titleThree h2', .5, { x: '0', autoAlpha: 1, ease: Linear.easeNone }, '-=0.25'); | ||
+ | tl.to('#titleThree p', .5, { autoAlpha: 1, ease: Linear.easeNone }, '-=.5'); | ||
+ | }; | ||
+ | function placeBlue() { | ||
+ | tl.to('#blue', .5, { x: 0, y: 0, ease: Power3.easeOut }); | ||
+ | tl.to('#discoveryTextContainer', .5, { borderLeft: '0px solid #EEE', ease: Linear.easeNone }); | ||
+ | tl.to('#titleThree h2', .5, { x: '-=8', autoAlpha: 0, ease: Linear.easeNone }, '-=0.5'); | ||
+ | tl.to('#titleThree p', .5, { autoAlpha: 0, ease: Linear.easeNone }, '-=.5'); | ||
+ | }; | ||
+ | |||
+ | function highlightRed() { | ||
+ | |||
+ | removeDescription(); | ||
+ | |||
+ | if (active === 'orange') { | ||
+ | placeOrange(); | ||
+ | } else if (active === 'blue') { | ||
+ | placeBlue(); | ||
+ | } else if (active === 'green') { | ||
+ | placeGreen(); | ||
+ | } | ||
+ | |||
+ | active = 'red'; | ||
+ | |||
+ | tl.to('#red', .5, { x: 10, y: 4, ease: Power3.easeOut }); | ||
+ | tl.to('#discoveryTextContainer', .5, { borderLeft: '6px solid #E84E0F', ease: Linear.easeNone }); | ||
+ | tl.to('#titleFour h2', .5, { x: '0', autoAlpha: 1, ease: Linear.easeNone }, '-=0.25'); | ||
+ | tl.to('#titleFour p', .5, { autoAlpha: 1, ease: Linear.easeNone }, '-=.5'); | ||
+ | }; | ||
+ | function placeRed() { | ||
+ | |||
+ | tl.to('#red', .5, { x: 0, y: 0, ease: Power3.easeOut }); | ||
+ | tl.to('#discoveryTextContainer', .5, { borderLeft: '0px solid #EEE', ease: Linear.easeNone }); | ||
+ | tl.to('#titleFour h2', .5, { x: '-=8', autoAlpha: 0, ease: Linear.easeNone }, '-=0.5'); | ||
+ | tl.to('#titleFour p', .5, { autoAlpha: 0, ease: Linear.easeNone }, '-=.5'); | ||
+ | |||
+ | }; | ||
+ | |||
+ | document.addEventListener("DOMContentLoaded", setup);</script> | ||
</body> | </body> | ||
</html> | </html> |
Revision as of 13:06, 28 October 2017
Barriers
Click on the Segments in the Pie Chart to learn about the barriers to enter the insulin market.
Technical Barriers to Entry
In the current manufacturing world, recombinant methods are seen as difficult and time intensive. As a result of this, many avoid using recombinant technologies for therapeutic production regimes.
Legal Barriers to Entry
It took our iGEM team a full couple of months before we were comfortable to say that we had a new insulin to add to the market. We were also able to utilize expertise to navigate through the legal sphere, which greatly aided our process. In general though, due to the number of analogue insulins under patent, its very difficult to ‘create’ a new insulin.
Market Barriers to Entry
Every 5 years, the Australian governments Pharmaceutical Benefits Scheme undergoes negotiation with the respective manufacturing plants and suppliers to discuss price points for that period.
This system ultimately favours highly established, elite market players with the market scale to supply an entire region.
Cost Barriers to Entry
When people say ‘nothing comes cheap,’ they’re really talking about drug development. To say its expensive really undermines the meaning of expensive. Clinical trials generally cost around US$1 Billion to start with. Production plants for insulin manufacturing can fall anywhere between US$100-$500M, and then a license can cost up to another US$100M. Understandably, these costs limit majority of the wishful market entrants.